Last 46.35 INR
Change Today -2.60 / -5.31%
Volume 25.2K
As of 6:24 AM 08/28/14 All times are local (Market data is delayed by at least 15 minutes).

lincoln pharmaceuticals ltd (LPH) Snapshot

Open
50.00
Previous Close
48.95
Day High
50.00
Day Low
46.10
52 Week High
01/9/14 - 53.70
52 Week Low
09/30/13 - 24.90
Market Cap
756.0M
Average Volume 10 Days
34.6K
EPS TTM
3.14
Shares Outstanding
16.3M
EX-Date
--
P/E TM
14.8x
Dividend
0.60
Dividend Yield
1.29%
Current Stock Chart for LINCOLN PHARMACEUTICALS LTD (LPH)

Related News

No related news articles were found.

lincoln pharmaceuticals ltd (LPH) Related Businessweek News

No Related Businessweek News Found

lincoln pharmaceuticals ltd (LPH) Details

Lincoln Pharmaceuticals Limited manufactures, markets, and exports pharmaceuticals products in India and internationally. Its product categories comprise antimalarial, antibiotics, anti-bactarials, analgesics, anti-inflammatory, anti-hypertensives, anti-fungal, antacids, anti-ulcers, anthelmintics, anti-cold, anti-allergic, anti-asthmatics, anti-emetics, gastrointestinal-agents, anti-diarrhoeals, anti-spasmodics, and pro-biotics. The company also offers cream, ointment, anti-infectives, vitamins, minerals, and iron-preparations. In addition, it also trades finished goods, chemicals products, and bulk drugs. The company was founded in 1979 and is based in Ahmedabad, India.

Founded in 1979

lincoln pharmaceuticals ltd (LPH) Top Compensated Officers

Joint Managing Director and Director
Total Annual Compensation: 1.2M
Managing Director, Whole Time Director, Membe...
Total Annual Compensation: 1.2M
Whole-Time Director and Member of Shareholder...
Total Annual Compensation: 1.2M
Compliance Officer, Whole-Time Director and M...
Total Annual Compensation: 475.0K
Compensation as of Fiscal Year 2013.

lincoln pharmaceuticals ltd (LPH) Key Developments

Lincoln Pharmaceuticals Ltd. Reports Unaudited Consolidated and Standalone Earnings Results for the First Quarter Ended June 30, 2014

Lincoln Pharmaceuticals Ltd. Reported unaudited consolidated and standalone earnings results for the first quarter ended June 30, 2014. For the quarter, the group reported net sales of INR 469.495 million, profit from operations before other income, finance costs and exceptional items of INR 60.593 million, profit from ordinary activities before tax of INR 42.123 million and net profit after taxes, minority interest and share of associates of INR 32.284 million or INR 1.98 per diluted share after extraordinary items (not annualised) compared to net sales of INR 379.538 million, profit from operations before other income, finance costs and exceptional items of INR 41.818 million, profit from ordinary activities before tax of INR 27.295 million and net profit after taxes, minority interest and share of associates of INR 32.410 million or INR 1.99 per diluted share after extraordinary items (not annualised) reported in the same period last year. For the quarter, the parent company reported net sales of INR 463.706 million, profit from operations before other income, finance costs and exceptional items of INR 64.528 million, profit from ordinary activities before tax of INR 50.718 million and net profit after taxes, minority interest and share of associates of INR 38.461 million or INR 2.36 per diluted share after extraordinary items (not annualised) compared to net sales of INR 374.260 million, profit from operations before other income, finance costs and exceptional items of INR 37.617 million, profit from ordinary activities before tax of INR 28.305 million and net profit after taxes, minority interest and share of associates of INR 35.004 million or INR 2.15 per diluted share after extraordinary items (not annualised) reported in the same period last year.

Lincoln Pharmaceuticals Ltd., Board Meeting, Aug 14, 2014

Lincoln Pharmaceuticals Ltd., Board Meeting, Aug 14, 2014. Agenda: To consider unaudited consolidated and standalone earnings results for the first quarter ended June 30, 2014.

Lincoln Pharmaceuticals Ltd. Reports Audited Consolidated and Standalone Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2014

Lincoln Pharmaceuticals Ltd. reported audited consolidated and standalone earnings results for the fourth quarter and full year ended March 31, 2014. For the quarter, on consolidated basis, the company reported net sales/income from operations of INR 674.885 million, total income from operations of INR 667.570 million, profit from operations before other income, finance costs and exceptional items of INR 44.810 million, profit from ordinary activities before tax of INR 13.592 million, net profit of INR 7.734 million or INR 0.43 per basic and diluted share after extraordinary items compared to the net sales/income from operations of INR 575.544 million, total income from operations of INR 595.245 million, profit from operations before other income, finance costs and exceptional items of INR 68.285 million, profit from ordinary activities before tax of INR 45.212 million, net profit of INR 46.248 million or INR 2.51 per basic and diluted share after extraordinary items for the same quarter a year ago. For the year, on consolidated basis, the company reported net sales/income from operations of INR 2,090.858 million, total income from operations of INR 2,152.673 million, profit from operations before other income, finance costs and exceptional items of INR 191.159 million, profit from ordinary activities before tax of INR 120.712 million, net profit of INR 101.845 million or INR 6.53 per basic and diluted share after extraordinary items compared to the net sales/income from operations of INR 1,928.787 million, total income from operations of INR 1,995.652 million, profit from operations before other income, finance costs and exceptional items of INR 192.244 million, profit from ordinary activities before tax of INR 113.840 million, net profit of INR 95.343 million or INR 5.92 per basic and diluted share after extraordinary items for the previous year. For the quarter, on standalone basis, the company reported net sales/income from operations of INR 618.601 million, total income from operations of INR 631.523 million, profit from operations before other income, finance costs and exceptional items of INR 32.294 million, profit from ordinary activities before tax of INR 9.702 million, net profit of INR 5.788 million or INR 0.35 per basic and diluted share after extraordinary items compared to the net sales/income from operations of INR 586.164 million, total income from operations of INR 593.702 million, profit from operations before other income, finance costs and exceptional items of INR 52.080 million, profit from ordinary activities before tax of INR 33.070 million, net profit of INR 31.758 million or INR 1.95 per basic and diluted share after extraordinary items for the same quarter a year ago. For the year, on standalone basis, the company reported net sales/income from operations of INR 2,047.808 million, total income from operations of INR 2,098.913 million, profit from operations before other income, finance costs and exceptional items of INR 179.222 million, profit from ordinary activities before tax of INR 125.440 million, net profit of INR 114.276 million or INR 7.00 per basic and diluted share after extraordinary items compared to the net sales/income from operations of INR 1,909.205 million, total income from operations of INR 1,956.167 million, profit from operations before other income, finance costs and exceptional items of INR 184.850 million, profit from ordinary activities before tax of INR 113.250 million, net profit of INR 98.127 million or INR 6.02 per basic and diluted share after extraordinary items for the previous year.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
LPH:IN 46.35 INR -2.60

LPH Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for LPH.
View Industry Companies
 

Industry Analysis

LPH

Industry Average

Valuation LPH Industry Range
Price/Earnings 7.0x
Price/Sales 0.3x
Price/Book -- Not Meaningful
Price/Cash Flow 5.2x
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact LINCOLN PHARMACEUTICALS LTD, please visit www.lincolnpharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.